Biotricity, Inc. (OTC: BTCY) – Q2 2026 Earnings
Biotricity, Inc. (OTC: BTCY) – Q2 2026 Earnings
Press release and earnings call link
Earnings Release Date: Nov. 14, 2025
Stock Price: $0.52
Market Cap: $13.9 million
Q2 2026 sales of $3.9 million vs $3.3 million in the prior year
Q2 2026 EPS of ($0.03) vs ($0.07) in the prior year
Biotricity Inc. (OTCQB: BTCY)
Biotricity is a Technology-as-a-Service (TaaS) healthcare company specializing in cardiac diagnostics and remote patient monitoring. Its core product suite — including Biocore Pro, Bioflux, and Biocare — provides AI-powered cardiac monitoring solutions to hospitals, clinics, and home-based care providers.
Revenue Drivers: Subscription-based technology fees (recurring revenue from Biocore Pro and related services) make up nearly 90% of sales.
Customer Base: U.S. cardiologists, hospitals (via GPO networks), and emerging international clients (e.g., Canada, Saudi Arabia, Argentina).
Market Positioning: Positioned as an emerging leader in connected cardiac care and remote monitoring, with growing traction in adjacent verticals (pulmonary, neurology, sleep diagnostics).
Financial Trajectory: 19% YoY revenue growth to $3.9M, 82% gross margin, and positive EBITDA for two consecutive quarters — signaling near-term profitability.
Near-Term Focus: Scaling commercial operations, filing FDA for Biocore Pro 2, and expanding into international and adjacent health markets.
Competitive Advantage Insights
Press Release vs Call Transcript Comparison
The press release reads like an investor relations marketing document, designed to showcase scalability and vision.
The earnings call provides depth and financial clarity, with an emphasis on profitability trajectory and operational detail.
Together, they show a company transitioning from R&D to commercialization, with management confidence rooted in margin discipline rather than growth-at-all-costs.
The press release’s omission of free cash flow and profitability metrics may cause many investors to underestimate Biotricity’s financial turning point.
Positive Insights
Negative Insights
Investor Underappreciation Signals
✅ Operational Cash Flow Strength — Biotricity has achieved positive free cash flow for five consecutive quarters, but the press release only discussed net losses. Investors may overlook the liquidity strength that positions the firm for self-funded growth.
✅ Imminent FDA Filing (Biocore Pro 2) — Management revealed a concrete filing timeline for its next-generation cardiac device, missing from the PR. Investors might not yet price in this near-term regulatory catalyst.
✅ Economies of Scale Achieved — The call described Biotricity as having reached scale efficiency, meaning future revenue will drop straight to margin. This inflection point is understated in the PR and could surprise markets once profitability is reported.
✅ Strategic Contracts (VA & Home Care) — The call disclosed government and home health partnerships that extend beyond hospitals — absent from PR — potentially opening high-volume, recurring distribution channels.
✅ AI Efficiency Translation into Margins — Management connected proprietary AI to a 660 bps gross margin improvement. Investors may not realize this efficiency gain is recurring and scalable, not one-time.
Tariff Risk
No mention of U.S. tariffs or trade policy occurred during the call.
Biotricity’s business is domestic service- and software-based, with no discussion of hardware import exposure or supply chain dependencies affected by tariffs. Therefore:
No current tariff risk identified.
No mitigation strategies mentioned (e.g., supply shifts, pricing changes).
Future exposure could arise if the company scales manufacturing internationally for its Biocore Pro 2 device.
Assessment: Tariff risk negligible at present; monitor only if manufacturing footprint changes.
Hot Stock Trends Analysis
Previous Earnings Call
Quarter-over-quarter comparison
(No earnings call)Year-over-year comparison
Q2 FY2025 – “Proving the Model”
Biotricity focused on validation and discipline. Management highlighted its first positive EBITDA, cost reductions, and early traction from GPO partnerships. Tone was cautiously optimistic, emphasizing proof of concept, recurring revenue stability, and operational control as foundations for future scale.Q2 FY2026 – “Scaling the Model”
A year later, tone shifted to confident execution. The company reported two consecutive EBITDA-positive quarters and claimed economies of scale, shifting from cost management to growth investment. Focus turned to expanding commercial reach, FDA filing for Biocore Pro 2, and AI-driven efficiency gains.
Final Takeaway
Biotricity (OTC: BTCY) is in a growth-to-profitability transition phase, leveraging AI-driven automation and subscription-based cardiac diagnostics to expand margins and scale. The company’s positive EBITDA, recurring revenue dominance, and free cash flow stability position it for potential near-term profitability. While longer sales cycles and limited investor awareness remain risks, execution on FDA filings and contract conversions could meaningfully re-rate the stock.
Verdict: BUY, with upside contingent on sustained cash generation and regulatory progress.